These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35100460)

  • 1. Psoriatic patients with a history of cancer: A real-life experience with Apremilast treatment for 104 weeks.
    Bernardini N; Skroza N; Marchesiello A; Mambrin A; Proietti I; Tolino E; Maddalena P; Marraffa F; Rossi G; Volpe S; Potenza C
    Dermatol Ther; 2022 Oct; 35(10):e15306. PubMed ID: 35100460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.
    Gisondi P; Girolomoni G
    Drug Des Devel Ther; 2016; 10():1763-70. PubMed ID: 27307707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
    Radi G; Campanati A; Diotallevi F; Molinelli E; Offidani A
    G Ital Dermatol Venereol; 2019 Apr; 154(2):166-169. PubMed ID: 30229640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC; McNamee KE; McCann FE
    Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ▼ Apremilast for psoriasis and psoriatic arthritis.
    Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
    Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
    Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.
    Prescrire Int; 2016 Jun; 25(172):149-51. PubMed ID: 27486641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience.
    Radi G; Campanati A; Diotallevi F; Rizzetto G; Martina E; Bobyr I; Giannoni M; Offidani A
    Dermatol Ther; 2021 Nov; 34(6):e15179. PubMed ID: 34704350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections.
    Manfreda V; Esposito M; Campione E; Bianchi L; Giunta A
    Postgrad Med; 2019 Apr; 131(3):239-240. PubMed ID: 30700196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.
    Queiro Silva R; Armesto S; González Vela C; Naharro Fernández C; González-Gay MA
    Dermatol Ther; 2020 Nov; 33(6):e13961. PubMed ID: 32618402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-label studies on apremilast in dermatology: a review.
    Maloney NJ; Zhao J; Tegtmeyer K; Lee EY; Cheng K
    J Dermatolog Treat; 2020 Mar; 31(2):131-140. PubMed ID: 30935262
    [No Abstract]   [Full Text] [Related]  

  • 18. [Gastrointestinal side effects of apremilast : Characterization and management].
    Pinter A; Beigel F; Körber A; Homey B; Beissert S; Gerdes S; Staubach-Renz P; Radtke MA; Mössner R
    Hautarzt; 2019 May; 70(5):354-362. PubMed ID: 30937481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED
    Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Apremilast in Psoriasis: A Delphi Study.
    Carrascosa JM; Belinchón I; Rivera R; Ara M; Bustinduy M; Herranz P
    Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):115-134. PubMed ID: 31864537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.